Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Total Non-Current Liabilities data on file, last reported at $56.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 61.69% year-over-year to $56.7 million; the trailing twelve-month figure through Mar 2026 stood at $56.7 million (up 61.69% YoY), and the FY2025 full-year result was $69.8 million, up 70.48% from the prior year.
• Total Non-Current Liabilities retreated to $56.7 million in Q1 2026, from $69.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $69.8 million in Q4 2025 to a low of $15.2 million in Q2 2023.
• A 5-year average of $32.1 million and a median of $33.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities decreased 21.65% in 2023 and jumped 155.43% in 2024, its largest moves.
• Tracing PRLD's Total Non-Current Liabilities over 5 years: stood at $21.7 million in 2022, then soared by 71.58% to $37.2 million in 2023, then grew by 10.02% to $41.0 million in 2024, then surged by 70.48% to $69.8 million in 2025, then decreased by 18.84% to $56.7 million in 2026.
• Business Quant data shows PRLD's Total Non-Current Liabilities at $56.7 million in Q1 2026, $69.8 million in Q4 2025, and $33.3 million in Q3 2025.